VLX600
CAS No. 327031-55-0
VLX600( —— )
Catalog No. M21963 CAS No. 327031-55-0
VLX600 is an iron-chelating oxidative phosphorylation (OXPHOS) inhibitor, is a cell-permeable anticancer agent.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 46 | In Stock |
|
| 10MG | 73 | In Stock |
|
| 25MG | 150 | In Stock |
|
| 50MG | 245 | In Stock |
|
| 100MG | 419 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameVLX600
-
NoteResearch use only, not for human use.
-
Brief DescriptionVLX600 is an iron-chelating oxidative phosphorylation (OXPHOS) inhibitor, is a cell-permeable anticancer agent.
-
DescriptionVLX600 is an iron-chelating oxidative phosphorylation (OXPHOS) inhibitor, is a cell-permeable anticancer agent. It acts by reducing mitochondrial oxidative phosphorylation in tumor cells.VLX600 as a drug that is preferentially active against quiescent cells in colon cancer 3-D microtissues. The anticancer activity is associated with reduced mitochondrial respiration, leading to bioenergetic catastrophe and tumour cell death. VLX600 shows enhanced cytotoxic activity under conditions of nutrient starvation. Importantly, VLX600 displays tumour growth inhibition in vivo. (In Vivo):VLX600 (16 mg/kg; i.v.; every third day for 16 days) shows anti-tumor activity in human tumor xenografts.
-
In VitroVLX600 (6?μM; 72 hours) induces an autophagic response.VLX600 is cytotoxic to HCT116 spheroids. VLX600 induces a HIF-1α-dependent glycolytic response. VLX600 inhibits oxygen consumption in HCT116 cells. VLX600 inhibits phosphorylation of the mTOR downstream effectors 4EBP1 and p70-S6K by an HIF-1α-independent mechanism. VLX600 preferentially leads to decreased ATP levels in cancer but not normal cells.Cell Proliferation Assay Cell Line:HCT116, HT29, SW620, HT8, DLD and RKO cells Concentration:0.1, 1, 10, 100μM Incubation Time:72 hours Result:Inhibited the proliferation of these cells.Western Blot Analysis Cell Line:HCT116 cells Concentration:6?μM Incubation Time:72?hoursResult:LC3-II was induced.
-
In VivoVLX600 (16?mg/kg; i.v.; every third day for 16 days) shows anti-tumor activity in human tumor xenografts. Animal Model:NMRI nu/nu mice (HCT116 and HT29 colon cancer xenografts)Dosage:16?mg/kg Administration:Intravenously; every third day for 16 days Result:Anti-tumor activity was observed in both HCT116 and HT29 colon cancer xenografts.
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
Recptoroxidative phosphorylation (OXPHOS)
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number327031-55-0
-
Formula Weight317.35
-
Molecular FormulaC17H15N7
-
Purity>98% (HPLC)
-
SolubilityDMSO:8 mg/ml(25.21 mM)
-
SMILESC\C(=N/Nc1nnc2c(n1)[nH]c1c(C)cccc21)c1ccccn1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Xiaonan Zhang , M?rten Frykn?s , Emma Hernlund,et al. Induction of Mitochondrial Dysfunction as a Strategy for Targeting Tumour Cells in Metabolically Compromised Microenvironments[J].Nat Commun. 2014;5:3295.2. Karlsson H, et al. A novel tumor spheroid model identifies selective enhancement of radiation by an inhibitor of oxidative phosphorylation. Oncotarget. 2019 Sep 3;10(51):5372-5382.3. Arun Kanakkanthara , Kiran Kurmi , Thomas L Ekstrom, et al.BRCA1 Deficiency Upregulates NNMT, Which Reprograms Metabolism and Sensitizes Ovarian Cancer Cells to Mitochondrial Metabolic Targeting Agents[1].Cancer Res. 2019 Dec 1;79(23):5920-5929.
molnova catalog
related products
-
Przewalskinic acid A
Przewalskinic acid A is a rare, water-soluble, and highly biologically active ingredient found, thus far, only in the Salvia przewalskii Maxim herb.
-
Hydroxocobalamin
Hydroxocobalamin (Standard) is the analytical standard of Hydroxocobalamin. This product is intended for research and analytical applications. Hydroxocobalamin (Vitamin B12a) is an injectable naturally occurring form of vitamin B12 with a favorable adverse effect profile, used as a dietary supplement in the treatment of vitamin B12 deficiency including pernicious anemia.
-
(D-Tyr27·36,D-Thr32)...
(D-Tyr27·36,D-Thr32)-Neuropeptide Y (27-36)
Cart
sales@molnova.com